Compare CDMOs with comprehensive analytical services for release testing, stability, method development, and characterization. Filter by testing type, accreditation, and capacity.
873 companies listed
If the data isn't GMP, it doesn't count toward release or a filing — that's the whole game with analytical services. Every batch you release and every submission you make rests on analytical data: identity, assay, impurities, dissolution, sterility. A contract lab produces the evidence that your product meets spec. Cheap, non-GMP numbers can't be used for either purpose, so verify the quality system first. What are you actually buying? Release and stability testing under ICH conditions, method development and validation per ICH Q2, and the scientific depth to run down an out-of-specification result instead of just reporting it. Data integrity is now a top FDA inspection finding, so ask how they handle audit trails and chromatographic review. For biologics, confirm characterization and comparability capability, not just small molecule HPLC. 873 CDMOs here list analytical services. Compare them by testing scope, accreditation, and molecule type.
Analytical services underpin every stage of pharmaceutical development and manufacturing. From raw material testing through in-process controls to finished product release, analytical data provides the evidence that a drug product meets its specifications. GMP analytical laboratories must operate under validated methods, calibrated equipment, and documented procedures.
CDMOs offering analytical services range from full-service integrated organizations (manufacturing + analytics) to specialized contract testing laboratories. The most valuable analytical partners offer: method development and validation, release and stability testing, regulatory filing support (CTD Module 3), and the scientific depth to troubleshoot out-of-specification results.
United States
UPM Pharmaceuticals is a U.S.-based CDMO specializing in late-stage commercial manufacturing of semi-solid and oral solid dose products. Operating from a 475,000 sq ft cGMP FDA-registered facility in Bristol, Tennessee, UPM is a family-owned company with 30+ years of experience. They handle DEA-controlled substances and provide services from technology transfer and scale-up through commercial manufacturing. Capabilities include formulation development, analytical development, coated tablet manufacturing, pharmaceutical serialization, aggregation, and full packaging and warehousing.
Japan
PeptiStar is a Japan-based CDMO specializing in the development and cGMP manufacture of peptide and oligonucleotide APIs. From its 10,500 m² R&D and manufacturing site in Settsu, Osaka, the company supports programs from milligram-scale research material through clinical and commercial production. PeptiStar works with complex peptide structures, including long-chain, cyclic, branched and constrained peptides, non-natural amino acids and peptide conjugates. Its route-flexible manufacturing platform includes conventional and microwave-assisted SPPS, STag-PS and SYNCSOL liquid-phase technologies. Integrated downstream capabilities include preparative and continuous chromatography, membrane concentration and lyophilization, with 300 L filter reactors, chromatography columns up to 450 mm and lyophilizers up to 500 L. Purification and subsequent processing are conducted in Class 100,000 controlled areas. PeptiStar also develops and manufactures oligonucleotide APIs and peptide–oligonucleotide conjugates. The company was recognised by Exelixis as its 2025 CDMO of the Year.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.